BEVERLY HILLS, California, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announced today that its subsidiary, Orocidin A/S, will initiate its toxicity program for Orocidin (QR-01) in January 2025. The program is expected to conclude by the third quarter of 2025, paving the way for Orocidin to launch its ...